Docmode Health Technologies (NSE:DHTL) Research & Development: ₹0.0 Mil (TTM As of Mar. 2025)


NSE:DHTL Docmode Health Technologies Ltd NSE:DHTL
14 GF Score
Price ₹40.50
! 3 Warning Signs
View Full Analysis

What is Docmode Health Technologies Research & Development?

Docmode Health Technologies NSE:DHTL 14 Research & Development is ₹0.0 Mil as of Mar. 2025. GuruFocus rates NSE:DHTL with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Docmode Health Technologies's Research & Development for the six months ended in Mar. 2025 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was ₹0.0 Mil.

Docmode Health Technologies  (NSE:DHTL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Docmode Health Technologies Research & Development Related Terms

Docmode Health Technologies Research & Development Historical Data

* Premium members only.

The historical data trend for Docmode Health Technologies's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Docmode Health Technologies Research & Development Chart

Docmode Health Technologies Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
0.00 0.00 0.00 0.00 0.00

Docmode Health Technologies Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:DHTL
14GF Score
Docmode Health Technologies Ltd NSE:DHTL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Docmode Health Technologies Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Docmode Health Technologies (NSE:DHTL) has a Research & Development of ₹0.0 Mil as of Mar. 2025. Research and development expense is the total cost for research and development activities. View historical data on Docmode Health Technologies and its competitors.
Is Docmode Health Technologies' Research & Development too high?
Docmode Health Technologies' current Research & Development is ₹0.0 Mil. Overall, Docmode Health Technologies has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Docmode Health Technologies' Research & Development compare to VEEV and BTSG?
Docmode Health Technologies' Research & Development of ₹0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Docmode Health Technologies and its competitors. Docmode Health Technologies's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Docmode Health Technologies stock overvalued right now?
Docmode Health Technologies (NSE:DHTL) has a current Research & Development of ₹0.0 Mil. The current Research & Development is ₹0.0 Mil. Docmode Health Technologies' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Docmode Health Technologies (NSE:DHTL), the current Research & Development is ₹0.0 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Docmode Health Technologies Business Description

Address Chincholi Bunder Road, 201, Kalpataru Plaza, Rambaug Off, Nadiyawala Colony 2, Malad, Mumbai, MH, IND, 400064
Docmode Health Technologies Ltd is engaged in the business of providing comprehensive & interactive learning programs for healthcare professionals through e-Learning measures and providing online CME (continuous medical education) Certification Courses and designing & conducting surveys, quizzes, questionnaires, etc. for collecting data insights related to the healthcare industry Its business segment is engaged in providing vocational training, DocMode is a platform that provides authoritative, comprehensive, and interactive learning programs for Health Professionals - Doctors, Nurses, Allied and Medical Students - across the world. The company has a new segments namely publishing of Medical books, trading of medical books and journals, conducting customised and inhouse events.
14GF Score

Get the complete analysis for NSE:DHTL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹40.50
Price